Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

This study has been completed.
Information provided by (Responsible Party):
Array BioPharma Identifier:
First received: July 22, 2012
Last updated: April 21, 2016
Last verified: April 2016
This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162 and paclitaxel. Patients will receive increasing doses of study drug in combination with paclitaxel in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 36 patients from the US will be enrolled in this study.

Condition Intervention Phase
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Drug: MEK162, MEK inhibitor; oral
Drug: Paclitaxel, mitotic inhibitor; intravenous
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Array BioPharma:

Primary Outcome Measures:
  • Establish the recommended Phase 2 dose of study drug administered on continuous and intermittent schedules in combination with paclitaxel. [ Time Frame: One year ]

Secondary Outcome Measures:
  • Characterize the safety profile of the study drug in combination with paclitaxel in terms of adverse events and clinical laboratory tests. [ Time Frame: One year ]
  • Assess the efficacy of the study drug in combination with paclitaxel in terms of tumor response, duration of response and progression-free survival. [ Time Frame: One year ]
  • Assess the potential plasma pharmacokinetic (PK) interactions between study drug, metabolites and paclitaxel in terms of plasma concentrations and noncompartmental PK parameters. [ Time Frame: One year ]
  • Assess possible PK/efficacy and PK/safety correlations. [ Time Frame: One year ]
  • Assess potential predictive biomarkers of clinical activity for the study drug in combination with paclitaxel. [ Time Frame: One year ]

Estimated Enrollment: 36
Study Start Date: July 2012
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MEK162 + paclitaxel Drug: MEK162, MEK inhibitor; oral
multiple dose, escalating
Drug: Paclitaxel, mitotic inhibitor; intravenous
multiple dose, single schedule


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Histologically confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer (measurable or evaluable, nonmeasurable disease) that is platinum-resistant or refractory. In the judgment of the Investigator, a patient who is platinum-sensitive but would not benefit from further platinum treatment is also eligible.
  • Must have had ≥ 1 prior platinum-based chemotherapeutic regimen containing carboplatin, cisplatin or another organoplatinum compound for management of primary disease. This initial treatment may have included intraperitoneal (IP) therapy, consolidation, non-cytotoxic agents or extended therapy administered after surgical or non-surgical assessment.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
  • Available archival tumor sample (excisional or core biopsy) that can be acquired and provide consent to biomarker testing of the tumor.
  • Additional criteria exist.

Key Exclusion Criteria:

  • History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
  • Prior therapy with a MEK inhibitor.
  • History of hypersensitivity to taxanes or drug formulations containing Cremophor®.
  • History of acute coronary syndromes.
  • Uncontrolled or symptomatic brain metastases that are not stable, require steroids, are potentially life-threatening or that have required radiation within 28 days prior to first dose of study treatment.
  • Concomitant malignancies or previous malignancies with less than a 5-year disease-free interval at the time of enrollment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may enroll irrespective of the time of diagnosis.
  • Known positive serology for the human immunodeficiency virus (HIV), active hepatitis C, and/or active hepatitis B.
  • Treatment with ritonavir at the time of first dose of study treatment.
  • Treatment with continuous or intermittent small molecular therapeutics, biologic therapy or hormonal therapy within 28 days prior to first dose of study treatment.
  • Treatment with a cyclical chemotherapy within a period of time that is less than the cycle length used for that treatment prior to first dose of study treatment.
  • Treatment with any other investigational agents within a period of time that is less than the cycle length used for the treatment or within 28 days (whichever is shorter) prior to first dose of study treatment.
  • Treatment with prior radiotherapy within 21 days prior to first dose of study treatment; however, if the radiation portal covered ≤ 10% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy.
  • Additional criteria exist.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01649336

United States, Arizona
Scottsdale, Arizona, United States
United States, Indiana
Lafayette, Indiana, United States
United States, New York
New York, New York, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
Sponsors and Collaborators
Array BioPharma
  More Information

Responsible Party: Array BioPharma Identifier: NCT01649336     History of Changes
Other Study ID Numbers: ARRAY-162-112
Study First Received: July 22, 2012
Last Updated: April 21, 2016

Additional relevant MeSH terms:
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Fallopian Tube Diseases
Adnexal Diseases
Genital Diseases, Female
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Ovarian Diseases
Endocrine System Diseases
Gonadal Disorders
Antimitotic Agents
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 24, 2017